Intelligence Report · ~15 min read
Pulmonary Hypertension · Rare Disease Therapeutic Area Assessment
4 signals · 1 insights · 18 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 24, 2026
Confidence
Moderate Confidence · 61%
Evidence
23 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Pulmonary Hypertension · Rare Disease integrates 4 signals, 1 executive insights, and 18 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 22, 2026
Study on Aerobic Exercise Benefits for Pulmonary Hypertension Patients
A clinical trial is assessing the impact of a rehabilitation exercise program on physical activity in pulmonary hypertension patients.
View detail - signalJul 16, 2026
FDA Grants Approval for ILOPROST ANDA214997 by BELOTECA
The FDA has granted approval for the ANDA214997 application for ILOPROST submitted by BELOTECA.
View detail - signalJun 19, 2026
Establishment of Pulmonary Hypertension Biorepository for Future Biomarker Discovery
The NIH is establishing a biorepository for patients with Pulmonary Hypertension to discover novel biomarkers.
View detail - signalJul 4, 2026
Study on Endothelial Cell Dysfunction in Pulmonary Hypertension Launched by NIH
The NIH is conducting a study to better understand pulmonary hypertension through various diagnostic tests and treatments.
View detail - regulatoryJul 22, 2026
Drug Trials Snapshots: YARTEMLEA
YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
View detail - regulatoryJul 22, 2026
Opportunities for patients and the public to be involved in the work of the MHRA
How we engage and involve patients and the public in our regulatory decision-making.
View detail - regulatoryJul 22, 2026
Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful.
View detail - regulatoryJul 22, 2026
FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.
View detail - insightJun 19, 2026
New NIH Biorepository for Pulmonary Hypertension: Strategic Implications for Biomarker Development
The establishment of a biorepository for Pulmonary Hypertension could lead to significant advancements in biomarker discovery, enhancing diagnostic and therapeutic strategies. This initiative may reshape competitive dynamics in the PH market, necessitating close observation by pharma companies involved in this therapeutic area. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 18 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Drug Trials Snapshots: YARTEMLEA
83%YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Source: FDA
View evidenceOpportunities for patients and the public to be involved in the work of the MHRA
83%How we engage and involve patients and the public in our regulatory decision-making.
Source: MHRA
View evidenceCondition-Specific Meeting Reports and Other Information Related to Patients' Experience
72%This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful.
Source: FDA
View evidenceFDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry
72%Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.
Source: FDA
View evidenceDomperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
72%The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.
Source: MHRA
View evidenceWithdrawn | Cancer Accelerated Approvals
95%This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
Source: FDA
View evidenceNew NIH Biorepository for Pulmonary Hypertension: Strategic Implications for Biomarker Development
61%The establishment of a biorepository for Pulmonary Hypertension could lead to significant advancements in biomarker discovery, enhancing diagnostic and therapeutic strategies. This initiative may reshape competitive dynamics in the PH market, necessitating close observation by pharma companies involved in this therapeutic area. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 13 ranked evidence items (5 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Study on Aerobic Exercise Benefits for Pulmonary Hypertension Patients
Trial Update
- FDA Grants Approval for ILOPROST ANDA214997 by BELOTECA
Regulatory Approval
- Establishment of Pulmonary Hypertension Biorepository for Future Biomarker Discovery
Pipeline Update
- Study on Endothelial Cell Dysfunction in Pulmonary Hypertension Launched by NIH
Trial Update
Insights
- New NIH Biorepository for Pulmonary Hypertension: Strategic Implications for Biomarker Development
Pulmonary Hypertension · Biomarkers